We re-initiate coverage on digital therapeutics (DTx) company
Digital Therapies for two major health challenges
Stress and infertility are two of the great health and societal challenges of our time. Both Bonzun’s products offer evidence-based treatments for these challenges, and Bonzun IVF have been shown reduce dropout rate after a first failed cycle from 60% to 18% and increase the probability of getting pregnant by 49%. After the new company was formed in 2021, the efforts to transform existing products into scalable offerings were concluded late last year. The optimization of the patient support for fertility treatments, Bonzun IVF, meant a major change in sales strategy and with it changes to the app’s paywalls, which resulted in a steep increase in paying subscribers late last year.
As for the stress treatment, Bonzun Evolve, previous pilots with the
Scene set for doubling of revenues in 2023 and 2024
In our model, we now expect Bonzun Evolve to outpace Bonzun IVF in 2023, with 2,000 Evolve-licenses sold in 2023 and 4,000 in 2024, at an averge price of 1,500 per license. After severe cost cutting measures in 2022 we see a fair chance for
With the share price down 71% during 2022,
Read full report here: https://www.emergers.se/bonzun_a2/
© Modular Finance, source